Atara Biotherapeutics (ATRA) Non-Current Deffered Revenue (2020 - 2024)
Atara Biotherapeutics' (ATRA) quarterly Non-Current Deffered Revenue came in at $470000.0 in Q3 2024, down 99.36% YoY from $73.9 million in Q4 2023, and down 17.11% on a QoQ basis from $567000.0 in Q2 2024.
Atara Biotherapeutics (ATRA) Non-Current Deffered Revenue (2020 - 2024) Analysis & Trends
Atara Biotherapeutics (ATRA) has 5 years of Non-Current Deffered Revenue data on file, last reported at $470000.0 in Q3 2024.
- Quarterly Non-Current Deffered Revenue fell 99.36% year-over-year to $470000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $470000.0 (down 99.36% YoY) and the FY2023 annual result came in at $37.6 million, down 51.22% from the prior year.
- Non-Current Deffered Revenue slipped to $470000.0 in Q3 2024, from $567000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $78.0 million in Q1 2023 to a low of $470000.0 in Q3 2024.
- A 5-year average of $39.9 million and a median of $39.9 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue surged 100.42% — and 2024, when it sank 99.36%.
- Tracing ATRA's Non-Current Deffered Revenue over 5 years: stood at $27.8 million in 2020, then surged by 100.42% to $55.7 million in 2021, then soared by 38.22% to $77.0 million in 2022, then sank by 51.22% to $37.6 million in 2023, then tumbled by 98.75% to $470000.0 in 2024.
- The last three Non-Current Deffered Revenue figures came in at $470000.0 (Q3 2024), $567000.0 (Q2 2024), and $719000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 470,000.00 |
| Jun 30, 2024 | 567,000.00 |
| Mar 31, 2024 | 719,000.00 |
| Dec 31, 2023 | 37.56 Mn |
| Sep 30, 2023 | 73.93 Mn |
| Jun 30, 2023 | 75.57 Mn |
| Mar 31, 2023 | 78.04 Mn |
| Dec 31, 2022 | 77.00 Mn |
| Sep 30, 2022 | 42.34 Mn |
| Jun 30, 2022 | 43.33 Mn |
| Mar 31, 2022 | 45.00 Mn |
| Dec 31, 2021 | 55.71 Mn |
| Sep 30, 2021 | 26.84 Mn |
| Jun 30, 2021 | 22.47 Mn |
| Mar 31, 2021 | 31.81 Mn |
| Dec 31, 2020 | 27.80 Mn |